Video Experimental Relacionado

Updated: Feb 23, 2026

Author Spotlight: Evaluation of Protein-Condensate Dynamics in Live Human Cells

Author Spotlight: Evaluation of Protein-Condensate Dynamics in Live Human Cells

Published on: January 5, 2024

Drogas alostéricas en condensados biomoleculares: caminos hacia adelante

Ruth Nussinov¹, Clil Regev², Hyunbum Jang³

¹Computational Structural Biology Section, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA; Cancer Innovation Laboratory, National Cancer Institute at Frederick, Frederick, MD 21702, USA; Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.

Drug discovery today

|February 21, 2026

Resumen

Los condensados biomacromoleculares, cruciales en la enfermedad, son el objetivo de los nuevos fármacos alostéricos. Esta investigación explora el descubrimiento de fármacos específicos de proteínas adaptados al condensado para mejorar el potencial terapéutico.

Área de la Ciencia:

La bioquímica es la bioquímica.
Biología Molecular Biología Molecular
Descubrimiento de Drogas Descubrimiento de Drogas

Sus antecedentes:

Los condensados biomacromoleculares son compartimentos sin membrana esenciales que regulan las funciones celulares como la señalización y la expresión génica.
Estos condensados juegan un papel importante en la patogénesis de enfermedades, destacando su potencial terapéutico.
El desarrollo actual de fármacos a menudo se dirige a la interrupción de las estructuras de condensado, que pueden carecer de especificidad.

Objetivo del estudio:

Investigar el potencial de los condensados biomoleculares para avanzar en el descubrimiento de fármacos alostéricos.
Explorar estrategias de desarrollo de fármacos alostéricos específicos de proteínas adaptados al condensado.
Para abordar los desafíos en la optimización de fármacos alostéricos altamente específicos.

Principales métodos:

Examen de dos clases de fármacos alostéricos.
Análisis de la relación entre las proteínas residentes en condensado y el comportamiento alostérico.
Exploración de estrategias para aprovechar los condensados biomoleculares en el diseño de fármacos.

Principales resultados:

Los fármacos alostéricos ofrecen una alta especificidad, un rasgo deseable para atacar las proteínas residentes en condensados.
Los condensados biomoleculares presentan un marco único para el desarrollo de nuevos agentes terapéuticos.
El estudio sienta las bases para una nueva era de descubrimiento de fármacos alostéricos dirigidos.

Conclusiones:

Los condensados biomoleculares se pueden aprovechar para desarrollar fármacos alostéricos altamente específicos, centrados en las proteínas.
Este enfoque promete superar las limitaciones de los actuales fármacos moduladores de condensados.
Una mayor investigación sobre los fármacos alostéricos adaptados al condensado podría revolucionar el tratamiento de las enfermedades.

Palabras clave:

La alosteria es un tipo de alosteria.cambio de conformación cambio conformacional.conjuntos conformacionales conjuntos conformacionales.la cooperatividad y la cooperatividad.los inhibidores de los inhibidores.Los condensados biomacromoleculares sin membrana son condensados macromoleculares sin membrana.

Más Videos Relacionados

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

A Protocol for the Identification of Protein-protein Interactions Based on 15N Metabolic Labeling, Immunoprecipitation, Quantitative Mass Spectrometry and Affinity Modulation

A Protocol for the Identification of Protein-protein Interactions Based on 15N Metabolic Labeling, Immunoprecipitation, Quantitative Mass Spectrometry and Affinity Modulation

Published on: September 24, 2012

Videos de Conceptos Relacionados

Cooperative Allosteric Transitions

Cooperative Allosteric Transitions

Cooperative Allosteric Transitions

Cooperative Allosteric Transitions

Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...

Cooperative Allosteric Transitions

Cooperative Allosteric Transitions

Allosteric Regulation

Allosteric Regulation

Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...

Allosteric Proteins-ATCase

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...

Ligand Binding and Linkage

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...